Search Market Research Report
C1 Inhibitors Market Size, Share Global Analysis Report, , 2020 – 2026
C1 Inhibitors Market By Source (Human Derived & Recombinant Derived C1 Inhibitors), By Mode of Administration (Intravenous & Subcutaneous), By End-User (Hospitals & Pharmacies), and By Regions - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026
Industry Insights
[197+ Pages Report] Facts and Factors have recently published the report titled “C1 Inhibitor Market” which illustrates that the global C1 inhibitors market was estimated at around USD 3,300 Million in 2020, and it is expected to provide revenue of about USD 9,800 Million by end of 2026, developing at a CAGR of around 18.6% between 2021 and 2026.
Market Overview
C1 inhibitors are a part of the superfamily of the protein tree named “serpin.” C1 inhibitors could also be referred to as “C1 esterase inhibitors.” Just like the other serpin candidates of the family, they also comprise of two parts: C-terminal and N-terminal.C1 inhibitors are a form of protease inhibitors entitled with the function of reducing self-consciousness of the complement system in order to preserve function and avoid any hazardous reaction. Normally, 0.25g/L is the quantity in which it is present in the blood; however, its level doubles on any inflammatory reaction. Generally, the increased levels of C1 are not desired as it can cause genital conditions such as hereditary or acquired angioedema. It is found to play an important role in the complement activation, regulation of blood coagulation, and production of fibrinolysis and kinins. C1 inhibitors are effective FXIIa inhibitors.
Industry Growth Factors
A high growth in the rise of hereditary angioedema (HAE) and the preferred use of prophylactic treatment will drive the market to higher growth. Additionally, benefits include treatment and prevention of acute attacks and routine prophylaxis against other forms of HAE. Other drivers for the C1 inhibitors market include a rise in awareness by various studies that show the effective nature of C1 inhibitors in the treatment of HAE diseases. Acquired investment pools from investors will also fuel the growth of the market during the forecast. C1 inhibitor medications are also used for short-term treatment for prophylactic diseases which increases their market footprint to a larger extent. Furthermore, the rising requirement for the treatment of HAE diseases coupled with the growing awareness regarding these diseases is all projected to drive the global C1 inhibitors market growth. Growing investments also fuel the market. The rising occurrence of HAE increases the demand for C1 inhibitors, thereby boosting the market during the forecast period. The advancements in the drugs and formulations along with the use of C1 inhibitors as short-term prophylactic medication are other factors that propel the market. Additionally, the rising adoption of the subcutaneous route of administration by doctors and improving availability of Ruconest further fuel the C1 inhibitor market.
However, a high initial cost and widened reimbursement times from third-party vendors for the operation will hinder the growth of the market to some extent. The lack of awareness and delay in approval tend to hamper the market growth. Also, misdiagnosis and costly medication are other factors likely to restrain the C1 inhibitors market growth.
Segmentation Analysis
The global C1 inhibitors market can be segmented on the basis of source, route of administration, end-users, and regions.
On the basis of source, the global C1 inhibitors market can be divided into human-derived and recombinant derived. The human-derived C1 inhibitors can be further broken down into CINRYZE, Berinert, and HAEGARDA while the recombinant derived C1 inhibitors can be bifurcated into Ruconest. On the basis of mode of administration, the global C1 inhibitors market can be divided into intravenous and subcutaneous. On the basis of end-users, the global C1 inhibitors market can be divided into hospitals and pharmacies.
Regional Analysis
North America is expected to occupy the largest market share during the forecast period in terms of market revenue. Factors for the heavy rise of the C1 inhibitors market are a well-established healthcare infrastructure, improved healthcare access, increased awareness about HAE treatments, and widened reimbursement support from healthcare providers. North America will be followed by Europe and Asia-Pacific in terms of growth during the forecast period.
Report Scope
Report Attribute |
Details |
Market Size in 2020 |
USD 3,300 Million |
Projected Market Size in 2026 |
USD 9,800 Million |
CAGR Growth Rate |
18.6% CAGR |
Base Year |
2020 |
Forecast Years |
2021-2026 |
Key Market Players |
Shire, CSL Behring, Lev Pharmaceuticals, Pharming Group, Salix Pharmaceuticals, Viropharma Biologics, Inc., Ionis Pharmaceuticals, Inc., iBio, Inc., Sanquin, and BioCryst Pharmaceuticals., among others. |
Key Segment |
By Source, By Mode of Administration, By End-User, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Competitive Players
The major participants in the global C1 inhibitors market are :
- Shire
- CSL Behring
- Lev Pharmaceuticals
- Pharming Group
- Salix Pharmaceuticals
- Viropharma Biologics Inc.
- Ionis Pharmaceuticals Inc.
- iBio Inc.
- Sanquin
- BioCryst Pharmaceuticals
By Source Segment Analysis
- Human Derived C1 Inhibitors
- CINRYZE
- Berinert
- HAEGARDA
- Recombinant Derived C1 Inhibitors
- Ruconest
By Mode of Administration Segment Analysis
- Intravenous
- Subcutaneous
By End-User Segment Analysis
- Hospitals
- Pharmacies
By Regional Segment Analysis
- North America
- U.S.
- Canada
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
Table of Content
Industry Major Market Players
- Shire
- CSL Behring
- Lev Pharmaceuticals
- Pharming Group
- Salix Pharmaceuticals
- Viropharma Biologics Inc.
- Ionis Pharmaceuticals Inc.
- iBio Inc.
- Sanquin
- BioCryst Pharmaceuticals
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors